Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. A number ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in t ...

Research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Dynavax Technologies in a report ...

Dynavax Technologies Corporation ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring ...

At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Ryan Spencer, whose company Dynavax technologies is ...

Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...